David M. Hyman, MD

Clinical Cancer Research Senior Editor

David M. Hyman, MD, is the Chief of the Early Drug Development Service and Co-Chair of the Center for Mechanism Based Therapy (CMBT) at Memorial Sloan Kettering Cancer Center in New York City, as well as a senior editor for Clinical Cancer Research. His personal research focuses on first-in-human studies as well as multi-histology, genomically-selected "basket" studies.

A graduate of Brown University and Weill Cornell Medical College, Dr. Hyman completed his internal medicine residency at New York Presbyterian Hospital/Weill Cornell Medical College as an Assistant Chief Resident.

Dr. Hyman has been an active AACR member since 2013 and, in addition to his editorial duties for Clinical Cancer Research, he has held several leadership positions in the organization. Since 2015, he has been on the AACR Project GENIE Team and the AACR Clinical and Translational Research Fellowships Scientific Review Committee, and he is on his second term as a member of the AACR Annual Meeting Clinical Trials Tract Committee. He is currently co-chair of the scientific committee for AACR's 2020 Annual Meeting and co-chair of AACR’s Advancing Precision Medicine Drug Development conference that will be held in January 2020.

As an author, Dr. Hyman has published widely in several highly respected journals, including the New England Journal of Medicine, Nature, and AACR’s Cancer Discovery and Clinical Cancer Research. For his work, he received the 2015 NCI Clinical Team Leadership Award and the 2012 American Society of Clinical Oncology Merit Award.

Recent AACR Publications

• Impact of FDG PET Imaging for Expanding Patient Eligibility & Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, Neratinib.
  Ulaner GA…Hyman DM. Clinical Cancer Research 2019 [Epub ahead of print].
• First-in-Human Phase I Study of the Activin A Inhibitor, STM 434, in Patients with Granulosa Cell Ovarian Cancer and Other Advanced Solid Tumors.
  Tao JJ…Hyman DM. Clinical Cancer Research September 2019.
• Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer.
  Soumerai TE…Hyman DM. Clinical Cancer Research December 2018.
• Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors.
  Hyman DM…Dar M. Clinical Cancer Research June 2018.
• A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.
  Drilon A…Hyman DM. Cancer Discovery August 2017.
• Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated Toxicities.
  Eaton A…Hyman DM. Clinical Cancer Research January 2016.
• Prospective blinded study of BRAF^V600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders.
  Hyman DM…Abdel-Wahab O. Cancer Discovery January 2015.